VTD与TD方案用于治疗多发性骨髓瘤的疗效及安全性

Efficacy and Safety of VTD and TD in the Treatment for Multiple Myeloma

目的比较硼替佐米、沙利度胺及地塞米松(VTD)与沙利度胺联合地塞米松(TD)治疗多发性骨髓瘤(MM)的疗效和不良反应情况。方法选择80例MM患者,根据治疗方法均为2组,40例采用VTD方案进行治疗,另40例采用TD方案进行治疗。比较2组患者的治疗疗效和不良反应发生情况。结果VTD组的总有效率(77.5%)高于TD组(55.00%),差异有统计学意义(P<0.05)。VTD组过敏性皮疹发生率和周围神经病变发生率均高于TD组,差异有统计学意义(P<0.05);VTD组血小板减少症发生率(30.00%)与TD组(15.00%)相比,差异无统计学意义(P>0.05);其余不良反应组间差异无统计学意义(P>0.05)。结论VTD方案用于多发性骨髓瘤治疗的疗效优于TD方案,但VTD组的安全性略低于TD组。

Objective To compare the efficacy and adverse reactions of bortezomi,thalidomide,dexamethasone(VTD)and thalidomide combined with dexamethasone(TD)in the treatment of multiple myeloma(MM).Methods Eighty patients with MM were selected,according to the treatment methods,the 2 groups were divided into 2 groups.40 patients were treated with VTD,and 40 others were treated with TD.The therapeutic efficacy and adverse reactions of the 2 groups were compared.ResultsThe total efficiency rate of the VTD group(77.5%)was higher than that of the TD group(55.00%),and the difference was statistically significant(P<0.05).The incidence of allergic rashes and peripheral neuropathy in the VTD group were higher than that of the TD group,and the difference were statistically significant(P<0.05).The incidence of thrombocytopenia in the VTD group(30.00%)was not statistically significant compared to the TD group(15.00%)(P<0.05).The incidence of peripheral neuropathy(22.50%)and rash(52.50%)in the VTD group was higher than that of the TD group(5.00%,27.50%),and the difference was statistically significant(P<0.05).There was no statistically significant difference between the remaining adverse reaction groups(P>0.05).Conclusion The effect of VTD on multiple myeloma is better than that of TD,but the safety of VTD group is slightly lower than that of TD group.